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Primary biliary cirrhosis (PBC) tends to affect females more than males. PBC 
selectively damages intrahepatic small bile ducts, particularly interlobular bile ducts. 
The clinical presentation of PBC has changed according to recent advances in 
clinicobiological diagnosis and improvements in therapeutic effects and prognosis. In 
particular, we encounter PBC patients with hepatocellular carcinoma (HCC), and the 
number of these patients appears to have increased. The precise reason for the increased 
number of PBC patients with HCC in recent decades remains unknown, but recognizing 
the current status of carcinogenesis in PBC patients, identifying the associated 
clinicopathological risk factors, and understanding how the pathogenesis of PBC is 
directly associated with HCC, is important. In this review, we summarize the data from 
two nationwide surveys undertaken in Japan as well as recent data from Japanese and 
international studies. 
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 Primary biliary cirrhosis (PBC) is an autoimmune liver disease. It tends to 
affect females more than males. PBC selectively damages the intrahepatic small bile 
ducts, particularly interlobular bile ducts. Because of progressive loss of bile ducts, PBC 
develops into chronic cholestasis and finally biliary cirrhosis.  
 The clinical presentation of PBC has been changing over the years. In 
particular, the proportion of asymptomatic patients at diagnosis has increased. In 
contrast to other primary biliary diseases such as primary sclerosing cholangitis (PSC), 
the associated malignant tumor of PBC is hepatocellular carcinoma (HCC), although its 
incidence is low. The detailed clinicopathological significance and carcinogenesis of 
HCC associated with PBC remain unknown. In this review, recent data from Japan1 and 
other countries are reviewed. 
 
Complication of malignancy in patients with PBC 
 Several studies have indicated that PBC may be associated with an increased 
risk of extrahepatic malignancies as well as HCC, although they represent a rare 
complication. By surveying 212 Greek patients with PBC, 10.8% patients were 
diagnosed with malignancy, 3.8% patients with HCC, and 7.0% with extrahepatic 
malignancies.2 Moreover, a meta-analysis using PubMed and EMBASE databases 
revealed that PBC is closely associated with a greater risk of overall cancer and HCC, 
but not with other cancers.3 With respect to HCC, its incidence in patients with PBC 
varies from 0.76% to 5.9% depending on reports.2, 4-9 However, one report has stated 
that PBC is not risk factor for HCC.10 These divergent results may be because of the 
low prevalence of the association with HCC as well as geographical and environmental 
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differences. However, the number of PBC patients associated with HCC has been 
recently increased, which might be due to the improvement of therapeutic effects and 
prognosis.11-13  
 National surveys of patients with PBC in Japan have been undertaken 15 times 
biennially or triennially by the Intractable Hepato-Biliary Diseases Study Group for 
Research on Measures for Intractable Disease, which is supported by Health Labor 
Sciences Research Grants in Japan. The surveys involved 8509 patients registered in the 
1st–15th surveys performed between 1980 and 2012.9, 14, 15 According to the 15th 
National Survey performed in 2012, the incidence of malignancy at the time of 
PBC diagnosis was 3.3%. Liver cancer was the most common (24%), followed by 
gastric cancer (16%), colon cancer (12%), breast cancer (10%), uterine cancer (5%), 
thyroid cancer (6%), hematopoietic cancer (5%), ovarian cancer (3%), lung cancer (3%), 
and others (16%) 15.  
 
Risk factors for HCC in patients with PBC based on data from Japan and other 
countries 
 According to epidemiological studies by single and multiple centers, cirrhosis, 
portal hypertension, advanced age, diabetes mellitus (DM), being male, blood 
transfusion, smoking, and excessive intake of alcohol are reported as risk factors for 
HCC (in addition to infection by the hepatitis virus), but these risk factors vary among 
reports.4-7, 12, 16-18 Moreover, cases of patients with HCC arising from patients 
with non-cirrhotic PBC have been reported, and consideration of the carcinogenesis of 
HCC in PBC was noted. The Japanese data reported by Shibuya et al.6 highlighted the 
importance of age at the time of PBC diagnosis, male sex, and history of blood 
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transfusion as independent risk factors associated with the development of HCC by 
proportional hazards analyses. In general, autoimmune diseases (including PBC), 
irrespective of the organs affected, preferably affect females more than males, but the 
incidence of HCC in PBC and autoimmune hepatitis (AIH) is higher in males than in 
females.13 This difference in incidence between the sexes has been reported and 
confirmed in studies outside Japan.6, 7, 12, 17, 18. 
 
National survey of PBC with HCC in Japan 
 According to the 14th National Survey among patients with PBC with HCC in 
Japan, undertaken in 2009 among 2946 subjects (70 males, 2576 females) confirmed to 
either have or not have HCC as well as exclusion of hepatitis-B virus (HBV) carriers and 
HB antigen- and anti-hepatitis-C virus (HCV) antibody-positive patients, the incidence 
of HCC during follow-up was 2.4% (71/2946). This incidence was 5.1% (19/370) in 
males and 2.0% (52/2576) in females, and the proportion of males was 26.7%.1, 19 
Moreover, according to a cohort study by the National Hospital Organization Study 
Group for Liver Disease in Japan, 20 cases (2.0%) (male/female = 5/15; proportion of 
males, 25%) among the 1007 patients with PBC registered in 1989–2011 had HCC,20 
supporting a similar value for the incidence revealed by the National Survey of PBC in 
Japan. Therefore, in Japan, the incidence of HCC in patients with PBC and the 
proportion of males have been speculated to be 2% and 25%, respectively. Although the 
incidence of HCC is low, the incidence and mortality in patients with PBC are 
significantly higher than those in the general population of Japan based on detail analyses 
using the standardized incidence ratio and standardized mortality ratio (SMR) of HCC 
in patients with PBC.21. 
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 According to a comparative analysis of this population obtained from the 
National Surveys of patients with PBC in Japan (2009), male sex, old age, low serum 
albumin levels, low serum total cholesterol levels, advanced histological stage, and 
symptomatic status at the time of PBC diagnosis were significant risk factors for HCC 
(Table 1)1, 22. The cumulative incidence of carcinogenesis was 6.5% in males and 2.0% 
in females during the 10 years after PBC diagnosis; the difference between males and 
females was statistically significant (Fig. 1). In particular, analyses of the incidence of 
HCC in patients aged 10–80 years revealed that male patients with PBC in their forties 
and fifties had an increased risk of HCC compared with female patients with PBC in the 
same age groups. In multivariate analyses for risk factors of HCC, sex and histological 
stage were selected as the only significant factors among male sex, old age, low serum 
albumin levels, low serum total cholesterol levels, advanced histological stage, and 
symptomatic status raised by comparative analyses. By multivariate analyses for risk 
factors of HCC by sex, histological stage at the time of PBC diagnosis was an 
independent risk factor for HCC in females (Table 2), whereas no significant 
independent factors were selected in males (Table 3). With respect to histological stage, 
there was no difference in the proportion of males and females who 
underwent histological staging at the time of PBC diagnosis (Fig. 2). The incidence of 
histological stages 3 and 4 was approximately 16.0% in male and female patients with 
PBC without HCC (Fig. 2), whereas it was 14.2% and 57.1% in male and 
female patients with PBC with HCC, respectively.1, 22 Advanced histological stage was a 
risk factor for HCC in females but not in males (Fig. 2, Tables 2 and 3). Therefore, 
male patients with PBC should be followed-up to consider the possibility of 
complication with HCC in any PBC stage.  




Survey of patients with PBC with HCC in Japan 
 At the 47th Annual Meeting of the Liver Cancer Study Group of Japan, the 
survey of 178 patients with PBC with HCC (100 fatalities in the past years and 78 
patients followed-up) revealed that the proportion of males was 27.5% (49 males and 
129 females), which was similar to that from the National Survey of PBC in Japan. The 
average age at the time of PBC diagnosis was higher for males (68 years) than for 
females (62 years), but the time of HCC diagnosis was similar between males (73 years) 
and females (72 years; Fig. 3). Moreover, the duration between the diagnosis of PBC 
and that of HCC was shorter in males than in females (Fig. 3). 
HCC was simultaneously diagnosed during or before PBC diagnosis in 32.7% (16/49) 
males and 14.7% (19/129) females.  
 Clinicopathological data at the time of HCC diagnosis are shown in Table 4. 
There were more males with previous HBV infection and a history of alcohol 
consumption than females. There were no differences with respect to the history of 
blood transfusion, diabetes mellitus, apical membrane antigen levels, antinuclear 
antibody levels, body mass index, serum triglyceride levels, serum total cholesterol 
levels associated with nonalcoholic fatty liver disease (including nonalcoholic 
steatohepatitis), and use of ursodeoxycholic acid (UDCA; Table 4) between males and 
females. However, an analysis excluding patients with previous HBV infection and a 
history of alcohol consumption revealed no difference in other clinical findings, 
although the proportion of males (male/female = 24/104, 18.5%) remained higher than 
that of the male patients with PBC (male/female = 370/2576, 12.6%). Moreover, in 
females, the incidence of HCC gradually increased with the histological stage, whereas 
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that in males showed no trend or statistical significance. There was a significant 
difference in the distribution of the histological stage between males and females (Fig. 
4). An analysis of patients with PBC with HCC according to the histological stage 
revealed no clinical findings (including previous HBV infection and alcohol 
consumption) that were significantly different between patients with and without 
cirrhosis at the time of HCC diagnosis, suggesting that previous HBV infection and 
alcohol consumption are not directly associated with progression to cirrhosis in patients 
with PBC with HCC. 
 
Pathology of HCC in patients with PBC 
 With regard to the pathological findings of HCC, approximately two-thirds of 
patients showed a solitary mass, and there was no difference in sex according to the 
National Survey at the 47th Annual Meeting of the Liver Cancer Study Group of Japan. 
The degree of differentiation in HCC was mostly well-differentiated and moderately 
differentiated, and there was no difference in sex. Therefore, the risk factors and 
carcinogenesis of HCC differ between males and females, but the features of 
complicated HCC are common between males and females (Table 
5). As notable pathological findings, a survey of Japanese autopsy cases 
of PBC disclosed that fatty changes or bile plugs within tumors were frequently 
observed.23 Mallory body clusters and focal copper-binding protein deposition were 
consistently found in cirrhotic liver and carcinoma tissues. Moreover, HCC in patients 
with PBC was speculated to evolve through multiple steps because of the presence of 
dysplastic nodules in the peripheries of liver tissues.23 
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Carcinogenesis of HCC and its risk factors 
 Why does HCC develop in patients with PBC? PBC and PSC are typical 
biliary inflammatory diseases. PSC is a precursor lesion of 
cholangiocarcinoma, although based on the national survey in 2003,24 its incidence is 
relatively low in Japan (3.6%) compared with that in Europe and USA (7%–15%).25 In 
contrast, HCC is the associated malignancy with PBC (but not 
cholangiocarcinoma), even though the etiology and carcinogenesis of HCC associated 
with PBC remain unknown. In PBC, hepatic changes as well as cholangitis are involved 
in its pathogenesis.26 However, this hepatic activity causing hepatocellular damage is 
speculated to be involved in the carcinogenesis of HCC in patients with PBC. Differing 
from the direct hepatocellular damage associated with virus and autoimmune reactions 
found in viral and autoimmune hepatitis, hepatocellular damage associated with chronic 
cholestasis and chronic inflammation (including interface hepatitis) may be associated 
with carcinogenesis of HCC in patients with PBC. In PBC, chronic cholestasis occurs 
from an early stage of PBC, and mitogenic factors in the bile could 
be directly associated with PBC carcinogenesis.11, 23, 27, 28 
 
Cirrhosis  
 The incidence and mortality rate of HCC in Japanese patients with PBC are 
significantly higher than those in the general Japanese population.21 However, 
in patients with cirrhosis, the risk is considerably higher in PBC, and cirrhosis could be 
a risk factor of HCC irrespective of their etiologies. In Japan, PBC as an etiology of 
cirrhosis is observed in 2.4% cases.29 In the cirrhotic state, stress to the 
hepatocytes could be associated with HCC carcinogenesis. Moreover, most 
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female patients with PBC with HCC develop the advanced stage (including cirrhosis) at 
the time of HCC diagnosis (Fig. 3), supporting several reports stating that cirrhosis is a 
risk factor for HCC.6, 7, 17, 18 In contrast, Kuiper et al. 30 reported on the possibility that 
UDCA may protect against HCC. In UDCA-treated patients with PBC, the risk of 
HCC was relatively low, but the main risk factor for HCC was the absence of a 
biochemical response to UDCA and the development of cirrhosis. However, compared 
with females, the proportion of males with PBC with HCC was almost equally 
distributed among stages 1–4 (Fig. 4), suggesting a male-specific risk factor.  
 
Males  
 PBC affects females more than males, but the rate of carcinogenesis is higher 
in males than in females. However, the male-predominance of HCC is not exclusive to 
PBC, and is a common risk factor for developing HCC irrespective of its etiology. The 
reason for the rate of carcinogenesis being higher in males is speculated be because 
of the inhibitory mechanism of estrogen in the carcinogenesis of HCC. The 
inflammatory cytokine interleukin (IL)-6 is produced by Kupffer cells and is associated 
with constitutive damage and malignant transformation of hepatocytes in the 
development of HCC. During this HCC carcinogenesis, estrogen inhibits the 
development of HCC by attenuating the IL-6 production from Kupffer cells.31, 32 
Therefore, PBC affects females more than males, but with respect to the carcinogenesis 
of HCC, the estrogen deficiency-related HCC carcinogenesis is speculated to be closely 
associated with the high incidence of HCC in males. 
  
Previous HBV infection and excessive alcohol intake  
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 According to the 47th Annual Meeting of the Liver Cancer Study Group of 
Japan (2011), the time from the diagnosis of PBC to that of HCC is shorter in males 
than in females (Fig. 3). Moreover, the proportion of patients simultaneously 
diagnosed with PBC and HCC and with HCC before PBC was 32.7% in males and 
14.7% in females, and the ratio of these cases in males was significantly higher than that 
in females (Fig. 3)1. The reason for this significant difference is not because of the late 
diagnosis or underdiagnosis of HCC in males but because of the development of HCC 
from an early stage of PBC in males (Fig. 4). Moreover, the ratio of males with a 
history of HBV infection and excessive intake of alcohol was significantly higher than 
that of females (Table 4), suggesting that these risk factors could be associated with 
HCC carcinogenesis during the early stages in male patients with PBC. However, 
statistical analysis excluding these patients with these risk factors revealed that the 
incidence of HCC in males remained higher than that in females, suggesting that the 
male gender was not a confounding factor. Moreover, the ratio of previous HBV 
infection and excessive intake of alcohol was not significantly different between 
cirrhotic (Scheuer stage 4) and non-cirrhotic (Scheuer stages 1–3) patients, suggesting 
that at least these two factors are not associated with the development of cirrhosis in 
PBC patients with HCC.1 Among patients with a previous HBV infection, integration 
of the HBV gene into the human genome has been reported to be associated with 
HCC carcinogenesis,13 but the frequency and incidence of these patients among patients 
with PBC patients with HCC is not known. 
  
Conclusion 
 The difference between the sexes with regard to the association of HCC 
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among patients with PBC is an important risk factor in the HCC carcinogenesis 
in patients with PBC. However, it is not clear if HCC carcinogenesis is a specific 
mechanism for PBC. Moreover, in females, the development of cirrhosis is a risk 
factor for HCC in PBC. In males, HCC cases arising from an early PBC stage are not 
rare. Hence, male patients with PBC should be carefully followed-up from an early 
stage to identify HCC.  
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Fig. 1. Cumulative rates for appearance of hepatocellular carcinoma (HCC) in patients 
with primary biliary cirrhosis (PBC) according to sex. There is a statistically 
significant difference between males and females.  
 
Fig. 2. Histological stage of patients with primary biliary cirrhosis (PBC) with or 
without hepatocellular carcinoma (HCC) according to sex.  There is a 
significant difference in the proportion of female primary biliary cirrhosis 
(PBC) patients with HCC and those without.  
 
Fig. 3. Average age at the time of diagnosis of primary biliary cirrhosis (PBC) and 
hepatocellular carcinoma (HCC), and the duration between the diagnosis of 
PBC and that of HCC. The duration between the diagnosis of PBC and that of 
HCC is shorter in males than in females. 
  
Fig. 4. Histological stage according to sex at the time of hepatocellular carcinoma 
(HCC) diagnosis in patients with primary biliary cirrhosis (PBC). In females, the 
incidence of HCC gradually increases according to the histological stage, with a 
statistically significant difference.  
Clinical characteristics of patients with primary biliary cirrhosis 
(PBC) with or without hepatocellular carcinoma (HCC) at the time 
of PBC diagnosis (comparative analysis) 
HCC (+) HCC (−) p 
Case number 71 2875 
Sex (M:F)* 19:52 351:2524 0.0003 
Age (mean ±SD) 60.5 ± 10.4 56.4 ± 11.2 0.0023 
T-Bilirubin (mean ± SD) 1.37 ± 1.63 0.99 ± 1.52 0.1061 
Albumin (mean ± SD) 3.81 ± 0.58 4.05 ± 0.51 0.0002 
T-cholesterol (mean ± SD) 201.3 ± 60.5 217.4 ± 86.7 0.0397 
Histological stage* 
(I/II/III/IV) 
10/17/14/8 1060/662/263/66 <0.0001 
Use of UDCA (%) 89.7 91.8 0.5291 
Clinical stage  
(asymptomatic:symptomatic) 
38:33 2775/100 <0.0001 
Table 1 
Underlines denote statistically significant items.  *These are also selected as risk factors of 









Age  −0.0130 0.0174 0.56 0.9870 0.4531 
T-Bilirubin 0.0817 0.1171 0.49 1.0851 0.4852 
Albumin  −0.1771 0.3366 0.28 0.8376 0.5987 
T-cholesterol  0.0038 0.0033 1.32 1.0038 0.2512 
Histological stage 
(I/II/III/IV) 
−1.0255 0.1964 27.25 0.3586 <0.0001 
Use of UDCA (%) −0.1607 0.3151 0.26 1.3791 0.6100 
Clinical stage  
(asymptomatic:symptomatic) 
0.4252 0.1913 4.94 0.4271 0.0263 
Factors associated with the risk of hepatocellular carcinoma (HCC) at the 
time of primary biliary cirrhosis (PBC) diagnosis  in female patients with 
PBC (multivariate analyses) 
Table 2 









Age  −0.0542 0.0319 2.89 0.9472 0.0893 
T-Bilirubin −0.1018 0.1790 0.32 0.9032 0.5697 
Albumin  0.5884 0.5591 1.11 1.8011 0.2926 
T-cholesterol  0.0001 0.0020 0.00 1.0001 0.9511 
Histological stage 
(I/II/III/IV) 
0.2484 0.4096 0.37 1.2819 0.5443 
Use of UDCA (%) −0.5367 0.4254 1.59 2.9258 0.2071 
Clinical stage  
(asymptomatic:symptomatic) 
−0.3590 0.4635 0.60 2.0506 0.4385 
Table 3 
Factors associated with risk of hepatocellular carcinoma (HCC) at the time 
of primary biliary cirrhosis (PBC) diagnosis  in male patients with PBC 
(multivariate analyses) 
                                                 Male             Female        Total 
                                              (n = 49)          (n = 129)      (n = 178)                                            
            
Blood transfusion                    9%              8%             9% 
Past HBV infection*            33%           18%           22% 
Alcohol intake*   27%             2%                  9% 
Diabetes mellitus                  24%             23%                24% 
AMA level                             86%             82%               83% 
ANA level                              41%             49%               47% 
BMI (>25%)                           25%            31%                29% 
Triglyceride (>150)                8%               9%                 9% 
Total cholesterol (>220)        15%               9%                11% 
associated with NAFLD         0%             4%                 3% 
Use of UDCA    84%            84%          84% 
  Underlines denote statistically significant items. *p < 0.05 
Clinical characteristics of patients with primary biliary 
cirrhosis (PBC)at the time of hepatocellular carcinoma 
(HCC) diagnosis 
Table 4 
                                                 Male             Female          Total 
        
Number of HCC                  (n = 49)           (n = 128)      (n = 178)                                            
      Solitary                             65%      60%            62% 
      Multiple                            35%        38%             37%  
      Unknown                           0%           2%              2% 
                                                         
Differentiation of HCC         (n = 25)           (n = 41)       (n = 66)  
      Well        44%               37%           39%   
      Moderately     48%               56%           53% 
      Poorly                8%                 7%             8%  
Pathological characteristics of hepatocellular carcinoma (HCC) in 
patients with primary biliary cirrhosis (PBC) with HCC 
Table 5 
FemaleMale
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